Experts
    • Clinical Genetics (MD)
    • Otolaryngology
    • Plastic Surgery Within the Head and Neck
    Director of Medical Affairs, 23andMe
    Director of Medical Affairs, 23andMe
    Jeffrey D. Pollard, MD is a fellowship trained and double board certified physician and surgeon who joined 23andMe as Director of Medical Affairs in 2012 and is passionate about advancing the integration of personal genomics into the modern healthcare environment through educational initiatives and strategic partnerships with integral members of the healthcare system.
    • Clinical Genetics (MD)
    Chief Technology Officer of Claritas Genomics
    Chief Technology Officer of Claritas Genomics
    • Chief Technology Officer at Claritas Genomics
    John’s career has spanned pharmaceutical, next-gen sequencing, and genetic testing industries. Joining Claritas Genomics in 2014 as Chief Technology Officer, he has spearheaded novel genetic assays using NGS for diagnosing pediatric diseases and applying DNA sequencing to clinical problems. At Nabsys, he served as Head of Assay Development for three years and advanced the mapping and sequencing of DNAs hundreds of kilobases long using fully solid-state nanodetectors. Before that, he was Senior Director of Genomic Research at Helicos BioSciences for four years, helping to develop the first commercial single-molecule, next-generation sequencing platform and applying it to a range of DNA and RNA sequencing applications. These sequencing endeavors followed 20 years at Pfizer where he applied molecular biology and genetic approaches to identify novel therapeutic targets, to establish the genetic basis of drug response, and to characterize the genetics of drug-induced adverse events. Prior to joining industry, he was a Research Assistant Professor of Molecular Biology at Brown University researching lambda site-specific DNA recombination, DNA bending, and protein-DNA interactions. This followed a PhD from the University of California, Berkeley, Department of Chemistry, in which RNA and DNA structure and chemistry were studied. His BS in chemistry is from Yale University.
    • Internal Medicine
    • Medical Genetics
    Internist, Geneticist, Executive Committee Member of Johns Hopkins University/NIH Genetic Counseling Training Program
    Internist, Geneticist, Executive Committee Member of Johns Hopkins University/NIH Genetic Counseling Training Program
    Howard Levy, MD, PhD is board certified in and has been clinically practicing Internal Medicine since 1995 and Medical Genetics since 1999. He has extensive experience precepting and mentoring medical students, genetic counseling students, residents and fellows in multiple academic settings. He specializes in primary care of adults with genetic conditions, genetic risk assessment for common multifactorial diseases, pharmacogenetics and integration of genetics into primary care medicine. He provides medical services for adults with a wide variety of genetic disorders as well as general primary care patients, with whom he emphasizes genetic principles to improve routine care and preventive medicine. Dr. Levy is a co-developer and co-editor-in-chief of GeneFacts, an Internet-based clinical point of care information resource providing genetic information to non-geneticist clinicians, available at www.genefacts.org. Dr. Levy was a member of the review board for the NIH Office of Rare Diseases Research CETT (Collaboration, Education and Test Translation) Program for Rare Genetic Disease from its inception in 2005 through 2010 (when it ceased active operation). He is on the executive committee of the Johns Hopkins/NIH Genetic Counseling Training program, and has served on many of the masters and PhD committees of the program’s graduates. He has been invited (and served) annually as a clinical genetics mentor to trainees at the American Society of Human Genetics meeting since 2010, and has presented a session on family history annually at the American Society of Human Genetics High School Workshop since 2006.
    • Internal Medicine
    PI, Million Veteran Program, Department of Veterans Affairs
    PI, Million Veteran Program, Department of Veterans Affairs
    Dr Gaziano is a nationally and internationally recognized chronic disease epidemiologist. He has a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of coronary artery disease and stroke. Also of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. Recently, Dr. Gaziano has initiated a number of research projects to investigate the diverse nature of atherosclerosis. While atherosclerosis plaques form only in certain large and medium-sized vessels, the process of atherogenesis (the formation of plaque in the inner lining of arteries) affects arteries of all sizes. For example, cognitive decline and osteoporosis-related fractures have been linked to various cardiovascular disease risk factors, suggesting a role for small vessel disease in vascular dementia and in abnormal bone remodeling. These projects are intended to explore the extent to which atherosclerotic disease in small vessels leads to these and other chronic conditions, such as renal failure. Two internationally known and widely utilized resources are the centerpieces of his research: the Physicians' Health Study (PHS) and the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) databases. Dr. Gaziano is principal investigator for the internationally known PHS II study, a large-scale trial of vitamins in the prevention of chronic disease. He is also co-director of MAVERIC, which is one of three national centers of epidemiology funded by the Department of Veterans Affairs. Through MAVERIC, he recently became the principal investigator of the newly launched MVP (Million Veteran Program) study, which is in the process of recruiting a million participants for this major initiative in genetic epidemiology. In addition, he serves as the director of the Geriatric Research and Education Center (GRECC) at the VA Boston Healthcare System.
    • Clinical Genetics (MD)
    • Pediatrics
    Healthcare Consultant at Maine Medical Center
    Healthcare Consultant at Maine Medical Center
    Tom Brewster, MD, is a Healthcare Consultant at Maine Medical Center Physician Hospital Organization, where he works on health care delivery, payment reform, and genomic medicine. He is also on the Joint Advisory Committee of the Maine Genetics and Newborn Screening Program and Board of Directors of the New England Regional Genetics Group. Prior to the last 3 years, Dr. Brewster was an Attending Physician at Maine Medical Center for 33 years, where he was the Director of the Metabolism Program. Dr. Brewster received his medical school training at the University of Nebraska Medical Center. He went on to complete a pediatric residency at the University of Pennsylvania Children's Hospital of Philadelphia. Finally, he completed his Genetics and Metabolism Fellowship at the Harvard-affiliated Boston Children's Hospital. He is an Emeritus Fellow of the American College of Genetics and Genomics and FAAP.
    • Pediatrics
    • Medical Genetics
    Medical Genetics Resident
    Medical Genetics Resident
    • Chief Resident at University of Alabama at Birmingham, Department of Genetics
    Austin Hamm obtained his doctorate from the University of Tennessee Health Science Center and after completing his residency in General Pediatrics, entered fellowship in Medical Genetics at the University of Alabama at Birmingham. His primary academic interests are in pediatric genetics, inborn disorders of metabolism, and genetic defects associated with cancer predisposition. His work has been previously published in The Journal of Pediatrics, The American Journal of Medical Genetics, and Clinics in Perinatology. He lives in Birmingham, Alabama with his wife and son.
    • Clinical Genetics (MD)
    • Otolaryngology
    • Pediatrics
    Robin attended Albert Einstein College of Medicine in the Bronx, New York, where he also completed a residency in pediatrics. He then proceeded to do a fellowship in Genetics at The Children’s Hospital Philadelphia/University of Pennsylvania. His first faculty position was in the Department of Genetics at Case Western Reserve University School of Medicine in 1995. In 2003, Dr. Robin joined the newly created Department of Genetics at the University of Alabama at Birmingham. Dr. Robin is board certified in Clinical Genetics by the American Board of Medical Genetics. His clinical practice is primarily as a general medical geneticist, with expertise in pediatric genetics, syndrome identification and genetic counseling. His areas of focused interest include craniofacial disorders, and the genetics of deafness. While maintaining an active clinical practice, Dr. Robin has authored one book (Medical Genetics: Its Application to Speech, Hearing, and Craniofacial Disorders), 18 book chapters, over a dozen invited editorials and over 110 peer-review publications. His writings cover a wide range of topics in genetics and include descriptions and studies on a variety of genetic syndromes. He has published studies that have looked at genetics testing for deafness, and on ethical issues in genetic testing, including issues of confidentiality and duty to warn at risk relatives. Dr Robin’s other role is as an educator. He is the Medical Genetics residency program director, and is the President of the national Medical Genetics residency directors’ group. He also supervises all the educational activities of the department with respect to the University of Alabama School of Medicine (UASOM) as well as all other UAB residency programs.
    • Clinical Genetics (MD)
    • Pediatrics
    Medical Geneticist; Asst. Program Director for Medical Genetics residency programs
    Medical Geneticist; Asst. Program Director for Medical Genetics residency programs
    • Resident at Department of Genetics, University of Alabama at Birmingham

    Anna C.E. Hurst, MD, MS, is an assistant professor of medical genetics in the department of genetics at the University of Alabama at Birmingham. She trained as a genetic counselor at the University of South Carolina School of Medicine (Columbia) and then completed her medical degree at the Medical University of South Carolina (Charleston). She is a board-certified pediatrician who completed pediatrics residency at Wake Forest Baptist Health (Winston-Salem, NC) and a medical genetics residency at UAB. Hurst is a clinician for the UAB Undiagnosed Disease Program, skeletal dysplasia clinic, and general genetics, and she provides genetic inpatient hospital consultations for patients at UAB and Children’s of Alabama. She is passionate about education and is the Assistant Program Director for the UAB Medical Genetics residency programs, including categorical training and training combining genetics with pediatrics, internal-medicine, or maternal-fetal-medicine.  Her clinical interests include dysmorphology and congenital anomaly syndrome delineation, and she serves on the Scientific Advisory Board for Facial Dysmorphology Novel Analysis (FDNA). Her research focuses on expanding the availability of genomic sequencing for children with complex healthcare needs and incorporating phenotypic information into the interpretation of genomic data.

    • Medical Biochemical Genetics
    • Neonatal-Perinatal Medicine
    • Pediatrics
    • Medical Genetics
    • Languages: Finnish (native), English (fluent), Spanish (fluent), Swedish (relatively fluent), French (basics)
    Pediatrician, Neonatal (NICU) hospitalist, Medical Biochemical Geneticist, Clinical Geneticist, Co-Director of Pediatric Integrative Medicine (PIM) Residency program, Stanford Children's Hospital & Stanford University, California, USA
    Pediatrician, Neonatal (NICU) hospitalist, Medical Biochemical Geneticist, Clinical Geneticist, Co-Director of Pediatric...
    Annakaisa Niemi, MD, PhD, is a Clinical Instructor in the Department of Pediatrics, Divisions of Neonatology (primary), General Pediatrics and Medical Genetics at Stanford University. She is also a Co-Director of Pediatric Integrative Medicine (PIM) Residency program, a member of the Pediatric Integrative Medicine (IM) Core Group at Stanford Children's, and an Editor of the Metabolic Genetic chapters at PEMSoft/EBSCO. Dr. Niemi is the past Recipient of the Genzyme/ACMGF Clinical Genetics Fellowship in Biochemical Genetics Award (award period 7/2011-6/2012) and of the United Mitochondrial Diseases Foundation (UMDF) Clinical Fellowship Award (award period 8/2013-8/2014). Dr. Niemi's PhD thesis was on the role of mitochondrial DNA (mtDNA) in longevity and elite athletic performance. She has a special interest in Medical Biochemical Genetics, Medical Genetics, Pediatrics, Neonatology and Newborn Care, Integrative Medicine, Organ Transplants for Inborn Errors of Metabolism, and Palliative Care. Additionally, Dr. Niemi is active in blogging & writing (Facebook: Dr. AnnaKaisa, Twitter: @DrAnnakaisa). She has a special passion for creativity in science, medical education, making science & medicine understandable to everyone, children's & human rights, sustainability, and nature & outdoors.
    • Medical Genetics
    Division Head, Center for Medical Genetics at NorthShore University HealthSystem
    Division Head, Center for Medical Genetics at NorthShore University HealthSystem
    • Clinical Assistant Professor at Pritzker School of Medicine, University of Chicago
    Peter J. Hulick is a medical geneticist and the Division Head for the Center for Medical Genetics at NorthShore University HealthSystem. He has an appointment of Clinical Assistant Professor at the Pritzker School of Medicine, University of Chicago. Dr. Hulick received his undergraduate degree in biology from Northwestern University in Evanston, IL and his medical degree from Jefferson Medical College, in Philadelphia, PA. He completed an internal medicine residency at Mayo Clinic, Jacksonville, FL before pursuing his clinical medical genetics residency at Harvard Medical School. Current clinical interests, in addition to general genetic syndromes, include pharmacogenetics, cardiovascular and cancer genetics, and the integration of genomic information into the healthcare system. Current research activities include studies that identify and measure the influences of our genes on health and how to effectively manage these risks. He is also active in leading efforts to incorporate genomic information and testing into the NorthShore University HealthSystem.
    • Pediatric Hematology-Oncology
    Senior Physician, Pediatric Oncology Dana-Farber / Boston Children's
    Senior Physician, Pediatric Oncology Dana-Farber / Boston Children's
    Katherine A. Janeway, MD is a Senior Attending Physician in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute and Boston Children’s Hospital and an Assistant Professor of Pediatrics at Harvard Medical School. Her primary areas of research focus are: 1) understanding the application of cancer genomics to the pediatric oncology clinic and 2) identifying central oncogenic mechanisms, novel drug targets and new therapeutics for pediatric sarcomas – specifically gastrointestinal stromal tumor (GIST) and osteosarcoma – diseases in pediatric oncology particularly in need of scientific and clinical advances. To facilitate a translational approach to research, Dr. Janeway has clinical expertise and clinical and administrative roles related to her research interests. As the leader of the Sarcoma Program for Dana Farber Boston Children’s Cancer and Blood Disorders Center, she is responsible for programmatic initiatives that will enhance our ability to offer the best options for treatment and clinical research to patients with sarcomas. As Vice Chair of the Children’s Oncology Group Bone Tumor Committee, she is involved in setting the clinical research agenda, and guiding protocol development for collaborative studies in the childhood bone tumors Ewing sarcoma and osteosarcoma. She sits on three local committees shaping development of clinical genomics at Dana Farber Cancer Institute and Boston Children’s Hospital. Finally, she is the co-chair of the target and agent prioritization committee for the pediatric Children’s Oncology Group, NCI-MATCH study. Dr. Janeway received her MD from Harvard Medical School in 2000 and a Masters of Medical Science from Harvard Medical School in 2008. She completed her residency in Pediatrics at Children’s Hospital Boston, where she later served as Chief Resident. Dr. Janeway then completed her fellowship in Pediatric Hematology-Oncology at Dana-Farber Cancer Institute/Boston Children’s Hospital, where she joined the staff in 2007.
    • Medical Biochemical Genetics
    • Pediatrics
    • Medical Genetics
    Medical Geneticist at the University of Utah
    Medical Geneticist at the University of Utah
    Dr. Longo received his M.D. and Ph.D. in molecular biology and pathology from the University of Parma, School of Medicine in Italy. He trained in Pediatrics, Medical and Biochemical Genetics at Emory University in Atlanta, Georgia, USA. Dr. Longo is board certified in medical genetics and clinical biochemical genetics. Currently, Dr. Longo is Professor of Pediatrics and Pathology at the University of Utah, Chief of the Division of Medical Genetics, Director of the Metabolic Service in the Department of Pediatrics, Director of the Training Program in Clinical Biochemical Genetics and Medical co-Director of the Biochemical Genetics and Newborn Screening Laboratories at ARUP laboratories in Salt Lake City. His research concerns the molecular bases of metabolic disorders and their identification through newborn screening. With the introduction of next-generation sequencing, he is exploring the effect of genetic variations on human diseases and metabolic processes. He has an active clinical research program directed toward the development of new therapies for patients with metabolic disorders.
    • Molecular Genetic Pathology
    • Ophthalmology
    • Director at Ocular Genomics Institute
    Dr. Eric Pierce is a full-time clinician scientist. He is the Director of the Ocular Genomics Institute, the Berman-Gund Laboratory for the Study of Retinal Degenerations, and the Electroretinography Service at Mass. Eye and Ear and Harvard Medical School. He is also the Solman and Libe Friedman Associate Professor of Ophthalmology at Harvard Medical School. As a group, retinal degenerations are a common cause of blindness. The overall goal of Dr. Pierce’s clinical and research program has been to improve the understanding of the molecular bases of inherited retinal degenerations and related cilia disorders so that rational therapies can be developed for these diseases. Dr. Pierce pursues his objectives through a combination of laboratory-based investigation of retinal biology and disease, clinical care of children and adults with retinal degenerative disorders, and clinical research. Dr. Pierce is currently working to develop gene therapy for several forms of retinal degeneration.